The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Macy’s Inc. has appointed Robert Chavez, former Hermes Americas CEO, to the board. He faces challenges influencing strategy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceutical Industries Ltd. ADR-0.28% $24.91B ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

Copyright © 2025 MarketWatch, Inc. All rights reserved.